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Pancreatic cancer is one of the deadliest human malignancies and little progress has
been achieved in its treatment over the past decades. Advances in our understanding of
the biology of this disease provide new potential opportunities for treatment. Pancreatic
cancer is preceded by precursor lesions, the most common of which are known as
Pancreatic Intraepithelial Neoplasia (PanIN). PanIN lesions, which are the focus of this
review, have a high incidence of Kras mutations, and Kras mutations are a hallmark of
the late-stage disease. We now know from genetically engineered mouse models that
oncogenic Kras is not only driving the formation of pancreatic cancer precursor lesions, but
it is also required for their progression, and for the maintenance of invasive and metastatic
disease. Thus, an enormous effort is being placed in generating Kras inhibitors for clinical
use. Additionally, alternative approaches, including understanding the role of Kras effector
pathways at different stages of the disease progression, are being devised to target Kras
effector pathways therapeutically. In particular, efforts have focused on the MAPK pathway
and the PI3K pathway, for which inhibitors are widely available. Finally, recent studies
have highlighted the need for oncogenic Kras to establish feedback mechanisms that
maintain its levels of activity; the latter might constitute alternative ways to target Kras
in pancreatic cancer. Here, we will review recent basic research and discuss potential
therapeutic applications.
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KRAS IN PANCREATIC CANCER INITIATION AND
MAINTENANCE
The association of mutant Kras with pancreatic cancer was estab-
lished decades ago (Almoguera et al., 1988; Smit et al., 1988); the
most common mutation is one amino-acid substitution in posi-
tion 12 of the Kras protein, leading to a glycine (G) to aspartic
acid (D) substitution, although other variants, such as G to V
are also common (for review see Pylayeva-Gupta et al., 2011).
The mutations compromise the ability of the Ras protein to
hydrolize GTP to GDP, thus effectively locking the protein in
an active conformation. Recent tumor genome sequencing stud-
ies have established the prevalence of mutant Kras in Pancreatic
Intraepithelial Neoplasia (PanINs), the most common precursor
lesions (Kanda et al., 2012), and in pancreatic cancer (Jones et al.,
2008; Biankin et al., 2012) with increased precision. Results from
these studies confirm the notion that over 90% of early stage
PanIN and invasive tumors express mutant Kras. It is interesting
to note, however, that efforts to use mutant Kras (detected in the
pancreatic juice) as biomarker of pancreatic cancer have not been
successful, as Kras mutations are common in an age-dependent
manner even in people who are devoid of pancreatic malig-
nancy (Yakubovskaya et al., 1995; Lu et al., 2002; Yan et al., 2005;
Parsons and Meng, 2009). Moreover, the likelihood of low-grade
PanINs that progress to pancreatic cancer is as yet unclear, as
those pre-neoplastic lesions also occur in the general population
at a much higher rate than pancreatic cancer (Singh and Maitra,
2007).
INITIATION
Insight into the functional role of oncogenic Kras during the
onset pancreatic cancer has been obtained using genetically engi-
neered mouse models of the disease. Several different approaches
were used to target expression of oncogenic Kras to the mouse
pancreas, and discussing all of them goes beyond the scope of
this review. Arguably, the first models to mimic the human
disease, specifically the progression of PanINs to invasive can-
cer, have been based on the expression of oncogenic Kras in
a tissue-specific manner, and from the endogenous Kras locus.
The endogenous Kras-based models rely on Pdx1-Cre (Hingorani
et al., 2003) or Ptf1a-Cre (Kawaguchi et al., 2002) to obtain tissue-
specific expression of Kras by Cre-mediated recombination of
a stop cassette placed in the Kras locus (Jackson et al., 2001).
Both Cre strains drive expression of the recombinase across all
the pancreatic lineages. However, Pdx-Cre is also expressed in
the duodenum, while Ptf1a-Cre is exclusively pancreas-specific
within the gastrointestinal tract. Pdx1-Cre;LSL-KrasG12D and
Ptf1a-Cre;LSL-KrasG12D mice are generally referred to as KC
(Hingorani et al., 2003; Olive and Tuveson, 2006). KC mice
express oncogenic Kras from the earliest stages of pancreatic
embryonic development. However, they have a normal pancreas
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at birth. PanINs are first noticed shortly after weaning, and they
progress in grade and number over time. Thus, KC mice pro-
vided the first line of evidence that mutant Kras was necessary
and sufficient for the initiation of pancreatic cancer. Progression
to invasive pancreatic cancer occurs sporadically, and usually in
older animals. KC mice have opened a whole field of pancreatic
cancer research, as they have served as the basis to interrogate
other signaling pathways and genetic events leading to pancre-
atic carcinogenesis (reviewed in Morris et al., 2010b), as well as
the effect of environmental factors. The slow progression to inva-
sive disease, however, limited the use of these mice for pre-clinical
studies. Based on the observation that tumor suppressor genes
are usually lost or inactivated in the human disease, KC mice
have been crossed with loss-of-function or mutant allele for Ink4a
(Aguirre et al., 2003) or p53 (Hingorani et al., 2005). The latter,
commonly known as KPCmice, are currently the most promising
preclinical model in pancreatic cancer, thanks to the development
of imaging techniques (such as high resolution ultrasound) that
allow individual animals to be evaluated for the presence and size
of tumors (Olive et al., 2009). While their response to standard of
care therapies for pancreatic cancer can resemble that observed in
human patients (Singh et al., 2010), it should be acknowledged
that this may not always be the case and preclinical studies should
be translated to human patients with caution. For instance, the
promising response observed in GEMs upon gemcitabine and
Hedgehog pathway inhibitors in KPC mice (Olive et al., 2009)
did not hold true in human patients enrolled in a recent clini-
cal trial (http://phx.corporate-ir.net/phoenix.zhtml?c=121941&
p=irol-newsArticle&ID=1653550&highlight=).
PANCREATITIS AND ONCOGENIC KRAS
The observation that Kras mutations occur at much higher
frequency than pancreatic cancer in humans is recapitulated
in mouse studies, where—although every single pancreatic
epithelial cell expresses mutant Kras from the early pancreas
development—PanIN lesions occur sporadically and only several
weeks after birth. Thus, it emerges that additional events, whether
genetic or epigenetic, need to occur to initiate carcinogenesis. One
of the best established risk factors for pancreatic cancer is pan-
creatitis. Chronic pancreatitis patients have an elevated risk of
developing pancreatic cancer (Lowenfels et al., 1993; Malka et al.,
2002; Whitcomb and Pogue-Geile, 2002). The potential effect of
acute pancreatitis on carcinogenesis is not as well understood in
humans. However, it is possible that even low, subclinical levels
of local or systemic inflammation might promote the formation
of PanINs, in presence of mutant Kras. In mice, both acute and
chronic pancreatitis have been shown to synergize with oncogenic
Kras to drive the onset of carcinogenesis. In mice that activate
the expression of the KrasG12V mutant in the adult pancreas, car-
cinogenesis only occurs upon induction of chronic (Guerra et al.,
2007) or acute (Guerra et al., 2011) pancreatitis. The latter find-
ing has been recapitulated in the recently described iKras* mouse
model of pancreatic cancer (Collins et al., 2012a), which will be
described in more detail later in this review. Moreover, even in KC
mice, the induction of acute pancreatitis leads to rapid and exten-
sive PanIN formation (Carriere et al., 2009, 2011; Morris et al.,
2010a). Taken together, the current literature suggests that genetic
events and environmental changes cooperate to induce pancreatic
carcinogenesis. However, how these elements contribute to cancer
onset in human is not yet fully understood.
MAINTENANCE
Human pancreatic cancer cell lines have been extensively used
to study the disease. They have also provided the first system to
address the role of oncogenic Kras in tumor maintenance, and to
gain insight in the biologic role of Kras signaling in tumors. Most
cell line studies have relied on traditional cell culture systems,
thus they did not recapitulate the three-dimensional relation-
ship within the tumor nor the interactions between tumor cells
and their microenvironment. Nevertheless, knock-down stud-
ies have identified Kras-dependent and independent human cell
lines, and identified a Kras “signature.” Amplification of not only
Kras, but also upregulation of genes involved in cell survival
as well as epithelial differentiation are key characteristics found
in the Kras-dependency signature and are predictive of Kras
“addiction” (Singh et al., 2009). More recently, ductal and quasi-
mesenchymal subsets of primary human tumors were identified
(Collisson et al., 2011). In addition to different morphology and
expression of ductal genes vs. mesenchymal-lineage genes—hence
the nomenclature—the two subsets differed in their dependence
on oncogenic Kras. In fact, ductal cells were Kras-dependent
both in vitro and when transplanted into immune-compromised
mice, while cell lines with quasi-mesenchymal characteristics
were Kras-independent.
Finally, the question of Kras dependency in pancreatic cancer
has been addressed in genetically engineered mice. The iKrasG12D
(iKras∗) model, recently described (Collins et al., 2012a), allowed
for the first time to express oncogenic Kras in an inducible, tissue-
specific and reversible manner. Thus, oncogenic Kras could be
turned off at different stages of carcinogenesis and the effects
studied. Kras inactivation in PanINs resulted in rapid tissue
remodeling: the PanIN cells re-differentiated into acinar cells, and
the desmoplastic stroma was cleared through an as yet not fully
understood mechanism. Kras inactivation in advanced PanINs
led to massive epithelial cell death, together with some redif-
ferentiation of acinar cells that then became proliferative and
partially repopulated the pancreas parenchyma. A similar effect
was seen with Kras inactivation in tumors. A further study includ-
ing metastatic pancreatic cancer (Collins et al., 2012b) and in vivo
imaging showed regression of primary tumors and metastases.
However, a subset of the tumor cells survived in a dormant
state, but could resume rapid growth upon Kras re-activation. In
terms of translational potential of these studies, it is worth noting
that Kras-independent tumors were not observed in this mouse
model, potentially indicating a mouse vs. human difference.
However, the tumors did broadly fall in a ductal and a quasi-
mesenchymal category, both of which required Kras for growth
in vivo. Primary tumor cell lines derived from iKras∗ mice carry-
ing a mutant allele of p53 were Kras-independent for their growth
in two-dimensional cell culture, but required Kras for three-
dimensional growth. Lastly, the persistence of some tumor cells
upon Kras inactivation indicates that Kras inhibitors—were they
to become available—might not completely “cure” pancreatic
cancer. The concern is for the surviving cells to eventually either
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become resistant to Kras, or grow back when Kras inhibition is
released. Thus, it will be important in the future to understand
the mechanism(s) that allow a subset of tumor cells to survive
Kras inhibition and achieve long-term dormancy (Figure 1).
BIOLOGIC ROLE OF KRAS IN PANCREATIC CANCER CELLS
(METABOLISM, MACROPINOCYTOSIS, REGULATION OF THE
STROMA AND THE INFLAMMATORY RESPONSE)
While the link between mutant Kras and pancreatic cancer has
been long established, the biological function of Kras signaling
in pancreatic cancer cells is still being investigated, and some
important progress in this area has been achieved only very
recently. iKras∗ mice were used to perform microarray expres-
sion analysis experiments. Interestingly, several genes involved
in metabolism were identified as regulated by Kras (Ying et al.,
2012). In fact, Kras appears to induce the switch between a
mostly aerobic metabolism, characteristic of the healthy pan-
creas, with an anaerobic mechanism mainly through the lactic
acid pathway, which is associated with cancer cells. Additionally,
it has also been shown that Kras regulates glutamine metabolism
through non-canonical methods to aid in the maintenance of the
tumor cell’s redox state (Son et al., 2013). Moreover, the activa-
tion of the reactive oxygen species detoxification program was
shown to be regulated by Kras (Denicola et al., 2011). Reactive
oxygen species (ROS) are thought to be mutagenic and pro-
mote cancer, while the ROS detoxification program is thought
to be beneficial to the cell by clearing away the toxic com-
pounds; however, the data presented by DeNicola et al. contra-
dict this concept. Specifically, the authors show that oncogenic
Kras promotes tumorigenesis by inducing expression of NRF2,
a key component in the ROS detoxification program, and that
reducing ROS levels is necessary for PanIN/cancer progression
(Denicola et al., 2011). Thus, if the ROS detoxification program
is impaired as it occurs in mice lacking NRF2 expression, then
pancreatic carcinogenesis is inhibited, indicating that this is a fun-
damental mechanism to allow cells to bypass early barriers to
carcinogenesis. Kras also regulates other key cellular functions
related with the elevated energy needs to cancer: macropinocy-
tosis, induced by oncogenic Kras, allows the cancer cells to
acquire albumin from the surrounding extracellular space, and
use it to produce Krebs cycle intermediates (Commisso et al.,
2013).
In addition to intracellular factors regulated by Kras, the inter-
actions between the tumor cells and their microenvironment
are also controlled by this oncogene, although the full extent
of this regulation and the mechanisms underlying it are as yet
poorly characterized. In iKras∗ mice, inactivation of oncogenic
Kras at any stage of carcinogenesis leads to loss of prolifera-
tion and Smooth muscle actin expression in the stroma (Collins
et al., 2012a). Those changes are consistent with the conver-
sion of an active stroma to scar-tissue like fibrosis. One of the
signals mediating the interaction between the tumor cells and
the surrounding fibroblasts within the stroma might be Sonic
Hedgehog, one of the Hedgehog pathway ligands that is secreted
by the tumor cells (Berman et al., 2003; Thayer et al., 2003), and
activates signaling in a paracrine manner in fibroblasts (Yauch
et al., 2008). However, it is likely that additional signals regulate
the interactions between Kras-expressing epithelial cells and the
surrounding microenvironment.
The formation of PanINs, in humans and mice, is accompa-
nied by infiltration of immune cells. Interestingly, the subsets
of immune cells that infiltrate are different than the immune
cells normally present within the pancreas, and include abun-
dant regulatory T cells and myeloid derived suppressor cells,
while excluding cytotoxic T cells (Clark et al., 2007). Thus, Kras
expressing epithelial cells establish early on an immune suppres-
sive environment, that allows tumor growth. The functional role
of the infiltrating cells is an area of active investigation, given
the potential to use modulation of the immune response in can-
cer therapy (for review see Jaffee et al., 2001; Clark et al., 2009;
Vonderheide and Bayne, 2013).
THE SEARCH FOR KRAS INHIBITORS
The recent data highlighting the importance of Kras in the main-
tenance of pancreatic cancer demonstrates the necessity for the
development of Kras inhibitors. While the ideal mechanism to
prevent Kras signaling would be to directly block the GTP-
binding site of Kras, an effective small molecule inhibitor has yet
to be identified. Instead, multiple groups have investigated the
efficacy of targeting Kras indirectly.
Following translation, Kras is farnesylated allowing the pro-
tein to associate with the membrane thus bringing it into contact
with Ras activating proteins. At themembrane Kras is activated by
Ras-GEFs, guanine nucleotide exchange factors, specifically SOS,
which aids in Kras binding GTP. Farnesyltransferase inhibitors
(FTIs) were initially thought to be the silver bullet for Kras
inhibition due to the requirement for this post-translational mod-
ification for the subsequent activation of Kras. A number of FTIs
have been tested in the clinic, such as Lonafarnib and Tipifarnib,
and have predominantly proven unsuccessful for Kras-driven
tumors (for review see Appels et al., 2005). This lack of success can
be attributed to the differences between the three Ras proteins.
The preclinical studies that induced most of the excitement for
the potential of FTIs were performed on Hras-dependent tumors
(Kohl et al., 1995). In contrast to Hras, Kras, and to some extent
Nras, can be geranyl-geranylated upon inhibition of the farnesyl-
transferase (Whyte et al., 1997). This alternate post-translational
modification provides Kras with an escape mechanism, enabling
it to continue to associate with the membrane and its activating
proteins.
This failure of the FTIs to successfully prevent Kras activity and
subsequent downstream signaling has prompted exploration of
other means of Kras inhibition. Recently, multiple groups have
investigated strategies to prevent Kras from reaching the mem-
brane. One such inhibitor, Deltarasin, is a small-molecule that
binds to the farnesyl-binding pocket of PDEδ (Zimmermann
et al., 2013). PDEδ interacts with farnesylated-Kras and aids in
the translocation of Kras to the membrane (Chandra et al., 2012).
Therefore, interaction between Deltarasin and PDEδ allows for
the farnesylation of Kras but prevents Kras from reaching the
membrane. Another inhibitor, Salirasib, targets the localization of
Kras to the membrane. In contrast to PDEδ inhibition, Salirasib
blocks Kras activity by dislodging the farnesylated protein from
the membrane (Weisz et al., 1999). Importantly, Salirasib has
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FIGURE 1 | Oncogenic Kras in pancreatic cancer progression and
maintenance. Oncogenic Kras drives PanIN formation and—in
combination with loss or mutation of tumor suppressors such as
p53—progression to invasive adenocarcinoma. Inactivation of oncogenic
Kras at the PanIN stage leads to regression of the lesions, through a
mechanism that includes cells death as well as re-differentiation of
PanIN cells to acini. Inactivation of oncogenic Kras in metastatic tumor
leads to tumor regression; however, a subset of tumor cells survive
Kras inactivation, possibly entering a dormancy status, and setting the
stage for tumor relapse.
already shown potential as a Kras inhibitor in preclinical and
clinical trials of pancreatic cancer (Laheru et al., 2012).
In addition to the inhibitors designed to block Kras from
reaching the membrane, others have devised means to prevent
Kras activity at the membrane by inhibiting the interaction
between Kras and its Ras-GEF SOS. Patgiri et al. have designed
a small molecule alpha-helix, using the hydrogen bond surro-
gate (HBS) approach, that interferes with the Ras-SOS interaction
and therefore blocks the exchange of GDP for GTP, subsequently
decreasing Ras activity (Patgiri et al., 2011). Recently, it has
been shown that Kras is acetylated, in addition to the aforemen-
tioned post-translational modifications, and the presence of the
acetyl group alters SOS ability to exchange GDP for GTP. Future
work will identify the role acetylation plays in the activity of
mutant Kras and hence downstream cellular changes. This new
discovery of Kras acetylation highlights another mechanism that
can possibly be exploited to target and inhibit Kras activation
(Figure 2).
This recent surge of inhibitors that prevent Kras activity indi-
rectly is extremely exciting and promising. These inhibitors allow
for the normal post-translational modification of the oncopro-
tein, removing need for alternative processing, but prevent its
activity by interrupting its localization to the membrane or block
the necessary interactions with its activating proteins. Clinical
success of such inhibitors could dramatically change the thera-
peutic outlook for pancreatic cancer patients.
DOWNSTREAM EFFECTORS OF KRAS AND THE BIOLOGY OF
PANCREATIC CANCER
Several effector pathways are activated downstream of Kras, in a
context and tissue-specific dependent manner (for review, Bar-
Sagi, 1992; Campbell et al., 1998, 2006, 2007; Cox and Der,
2002; Pylayeva-Gupta et al., 2011). The two pathways that have
been studied most in detail in pancreatic cancer are MAPK and
PI3K signaling. The MAPK pathway consists of a kinase cascade,
whereby Raf kinases are activated by Kras and, in turn, activate
MEK1/2. MEK kinases phosphorylate and activate ERK1/2 (for
review, see Dhillon et al., 2007). MAPK signaling is active in
PanIN lesions as well as in late-stage pancreatic cancer, both in
human tumors and in mouse (Hingorani et al., 2003). Two key
lines of evidence indicate the importance of this pathways dur-
ing carcinogenesis: forced activation of MAPK signaling through
overexpression of a constitutive form of Raf leads to PanIN/PDA
formation and, conversely, blocking MAPK signaling blocks the
onset of carcinogenesis (Ardito et al., 2012; Collisson et al., 2012).
In contrast, expression of a constitutively active form of PI3K did
not induce PanIN formation (Collisson et al., 2012). However,
the latter finding has been contested more recently, as in a dif-
ferent context activation of PI3K signaling does induce pancreatic
carcinogenesis, and inhibition of this pathway blocks carcinogen-
esis (Eser et al., 2013). It is therefore possible that both pathways
are important during disease formation. The question remains,
however, as to the relative importance of those signaling path-
ways both during cancer formation and in advanced tumors.
Moreover, eventual feedback mechanisms linking them have not
been explored in pancreatic cancer, but they have been identified
in other tumors and could lead to acquired resistance to inhibitors
(Emery et al., 2009; Corcoran et al., 2010; Dai et al., 2011).
Given that both MAPK and PI3K signaling are active in a large
number of tumor types, small-molecule inhibitors for each path-
way have been developed. The MAPK pathway can be blocked at
the level of Raf (such as Vemurafenib, PLX4032); however, recent
studies have highlighted the efficacy of Raf inhibitors is highly
dependent on the cellular context. Raf inhibition is effective in
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FIGURE 2 | Inhibitors of Kras and of its effector pathways. Simplified scheme of Kras signaling, with representative inhibitors of signaling components
indicated in red. The inhibitor list is not comprehensive.
Raf mutant tumors (such as melanoma); in contrast, the use of
Raf inhibitors in Kras mutant tumors results in the paradoxical
upregulation of MAPK signaling. Specifically, in tumors bear-
ing wild-type Raf but mutant Ras (such as pancreatic cancer),
Raf inhibitors create feedback activation of MAPK signaling by
inducing dimerization of cRaf with BRaf and interaction with
the oncoprotein Kras-GTP (Hatzivassiliou et al., 2010; Heidorn
et al., 2010; Poulikakos et al., 2011). Therefore, MEK inhibition
has emerged as a more promising therapeutic strategy. Preclinical
studies in both the KPC mouse model as well as patient-derived
xenografts have shown blocking the MAPK pathway at MEK
results in a decrease of cell proliferation and a subsequent halt
in tumor growth (Collisson et al., 2012; Walters et al., 2013).
Additionally, several MEK inhibitors are currently in clinical trials
for solid tumors (http://www.clinicaltrials.gov/).
Similarly, inhibitors of both PI3K and AKT have been devel-
oped (Engelman, 2009). While inhibition of PI3K is complicated
by the fact that there are multiple isoforms of the protein (for
review see Vanhaesebroeck et al., 2010), and not all isoforms
interact with Ras (Fritsch et al., 2013), preliminary studies in KPC
mice show reduced proliferation and tumor growth upon PI3K
inhibition (Eser et al., 2013). However, these results are not con-
sistent across all preclinical models. Tumors in a xenograft model
of pancreatic cancer were more sensitive to the blockade of MEK
than PI3K (Hofmann et al., 2012), but treatment of xenografts
with MEK and AKT inhibitors in combination increased the sen-
sitivity of the tumors to radiation (Williams et al., 2012). The
potential of MAPK and PI3K inhibition, alone or in combina-
tion, will likely be explored further in pancreatic cancer in the
near future.
In addition to the MAPK and PI3K pathways, other Kras
effectors have been shown to be active and functionally linked
to pancreatic carcinogenesis (for review see Vigil et al., 2010).
Inhibitors for components of those pathways, such as RalGDS,
have been described (Gus-Brautbar et al., 2012). It will be one of
the upcoming challenges to determine the relative importance of
the different Kras effectors at different stages of the disease, and
in individual cases of pancreatic cancer.
FEEDBACK MECHANISMS THAT REGULATE KRAS ACTIVITY
Since pancreatic cancer is associated with a mutant, constitu-
tively active form of Kras, it has been supposed that Ras activity
is constantly high in tumor cells. However, studies in mouse
models have led to the surprising observation that, even when
mutant Kras is present in every single cell of the pancreas from
the beginning of the organ’s embryonic development, the activ-
ity of downstream effectors of Kras is not elevated compared
to the control pancreas. In fact, elevated activity of Kras effec-
tors is first observed when the initial morphological alterations
occur. Several recent studies have pointed at the need for positive
feedback mechanisms to induce and maintain high Kras activ-
ity. For instance, ligand-driven EGFR activation is sufficient to
activate Kras signaling, and is required for pancreatic carcinogen-
esis at least during the initial stages (Ardito et al., 2012; Navas
et al., 2012). Other mechanisms of Kras activation include inflam-
matory stimuli such as those provided by the Nfκ B pathway
(Daniluk et al., 2012), as well as IL6 (Zhang et al., 2013a). Finally,
signaling pathways such as Wnt cross-talk with Kras to activate
the MAPK cascade (Zhang et al., 2013b). The relative importance
of these signaling pathways and their requirement at later stages
of carcinogenesis need to be studied in further detail. If needed
in invasive tumors, upstream regulators of Kras might provide
additional therapeutic strategies, to complement direct targeting
of Kras and inhibition of downstream effectors.
CONCLUSIONS AND OPEN QUESTIONS
The association of mutant Kras and pancreatic cancer has
been known for decades, and validated by recent genome-wide
sequencing studies. Our understanding of the regulation of Kras
activity in pancreatic cancer has increased recently thanks to
studies made possible by mouse models that mimic the human
disease. Moreover, a series of discoveries has brought to light
the multiple roles of Kras in pancreatic cancer, ranging from cell
metabolism to interaction with the tumor stroma. Kras is a key
oncogene during the onset of pancreatic cancer, and it is still
required—at least in a subset of tumors—in invasive mouse and
human pancreatic cancer. While resistance to Kras inhibition has
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been observed experimentally, it is still likely that direct inhibi-
tion of Kras would have at least a de-bulking effect on pancreatic
tumors. This approach might be tested in the clinic in the near
future, since new small molecule inhibitors for Kras are emerg-
ing. Mouse models provide a cautionary tale, as they indicate
that resistance to Kras inhibition might eventually arise. Thus,
it will be important to understand the mechanisms of acquired
resistance and devise ways to eradicate pancreatic cancer.
A different set of open questions relates to personalized
medicine for pancreatic cancer. Recent studies have indicated
that human pancreatic tumors might be subdivided in different
subsets with different biological characteristics and different sus-
ceptibility to Kras inhibition (Collisson et al., 2011). Moreover,
pancreatic cancer cell lines have been shown to have different
expression of cellular kinases, and have unique susceptibility to
inhibition of those kinases (Kothari et al., 2013). The appropriate
targeting of individual tumors might therefore depend on their
individual characteristics.
Finally, successful translation of basic research findings to the
clinic necessarily relies on identifying appropriate pre-clinical
models. Traditional subcutaneous transplantation of human cell
lines in immunocompromised mice has revealed poor predic-
tive value. A significant advancement over traditional, cell line
based transplantation models, is the use of patient-derived pri-
mary samples that represent individual tumors. When ortho-
topically transplanted in the pancreas, patient-derived xenografts
maintain, at least in part, the microenvironment of the origi-
nal tumor, with the caveat of lacking an intact immune system.
Genetically engineered mice recapitulate the step-wise progres-
sion of the human disease and have an intact immune system
and tumor microenvironment. Their clinical predictive value will
however have to be carefully evaluated with controlled stud-
ies, and further optimization might be necessary to improve
their translational potential. Going forward, a combination of
primary-tumor based xenografts and genetically engineered mice
might need to be used for preclinical validation of any new
thearapeutic.
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